Loading clinical trials...
Loading clinical trials...
Randomized PhIII Trial of Cetuximab, Bevacizumab & Biweekly Infusional 5FU/Leucovorin (FOLF-CB) vs. Oxaliplatin, Bevacizumab, & Biweekly Infusional 5FU/Leucovorin (Bev-FOLFOX) in First Line Treatment of Metastatic Colorectal Cancer
Conditions
Interventions
Bevacizumab
Oxaliplatin
+3 more
Locations
82
United States
Brimingham Hematology and Oncology
Birmingham, Alabama, United States
Hematology Oncology Associates
Phoenix, Arizona, United States
Northern AZ Hematology & Oncology Assoc
Sedona, Arizona, United States
Business Office - ACRC
Tucson, Arizona, United States
Cancer Care Associates of Fresno Medical Group, Inc (aka California Cancer Care)
Fresno, California, United States
Monterey Bay Oncology
Monterey, California, United States
Start Date
September 1, 2005
Primary Completion Date
June 1, 2007
Completion Date
June 1, 2009
Last Updated
February 15, 2019
NCT07446322
NCT07536113
NCT07416552
NCT07228832
NCT04657068
NCT06625775
Lead Sponsor
US Oncology Research
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions